Literature DB >> 8812167

Longitudinal behavioral and 6-[18F]fluoro-L-DOPA-PET assessment in MPTP-hemiparkinsonian monkeys.

W P Melega1, M J Raleigh, D B Stout, A A DeSalles, S R Cherry, M Blurton-Jones, G G Morton, S C Huang, M E Phelps.   

Abstract

Biochemical and behavioral criteria were established to determine the long-term stability of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced unilateral striatal dopamine deficiency in the vervet monkey. At time points over a 12-month period, post-MPTP striatal dopamine synthesis capacity was indexed with 6-[18F]fluoro-L-DOPA (FDOPA)-positron emission tomography. For the MPTP-treated subjects (n = 4), an intrasubject FDOPA influx rate constant (Ki) ratio method of right (lesioned) striatum/left (unlesioned) striatum values was used to assess changes in striatal activity. Striatal FDOPA Ki ratios differed less than 5% between studies conducted at 1-2, 5-7, and 9-11 months post-MPTP; these results indicated a stable MPTP-induced striatal lesion over this time period. At the 5-7 and 9-11 month time points, behavioral indices of the MPTP-induced deficits were obtained within a species-typical group setting. For three of the four subjects, persistent decrements in motoric, affiliative, and vigilance behavior were observed while the frequency of aggression toward group members was increased. At the 9-11 month time point, one subject showed a 30% improvement in the social measures, indicative of a partial recovery from the MPTP-induced behavioral decrements although its striatal FDOPAKi ratio remained unchanged. Thus, behavioral and noninvasive biochemical methods can provide complementary indices to assess individual differences in sensitivity to MPTP-induced deficits. Both types of data are required to determine lesion stability and, subsequently, the efficacy of interventions designed to restore normal function in this primate Parkinsonian model.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8812167     DOI: 10.1006/exnr.1996.0167

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  5 in total

1.  Stability of alpha-[11C]methyl-L-tryptophan brain trapping in healthy male volunteers.

Authors:  Pedro Rosa-Neto; Mirko Diksic; Marco Leyton; Shadreck Mzengeza; Chawki Benkelfat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-10       Impact factor: 9.236

2.  Cyclosporine, a P-glycoprotein modulator, increases [18F]MPPF uptake in rat brain and peripheral tissues: microPET and ex vivo studies.

Authors:  Goran Laćan; Alain Plenevaux; Daniel J Rubins; Baldwin M Way; Caroline Defraiteur; Christian Lemaire; Joel Aerts; André Luxen; Simon R Cherry; William P Melega
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07-05       Impact factor: 9.236

3.  Strain-dependent recovery of open-field behavior and striatal dopamine deficiency in the mouse MPTP model of Parkinson's disease.

Authors:  R K Schwarting; M Sedelis; K Hofele; G W Auburger; J P Huston
Journal:  Neurotox Res       Date:  1999-09       Impact factor: 3.911

Review 4.  Animal models of neurodegenerative disease: insights from in vivo imaging studies.

Authors:  Elissa M Strome; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

5.  Social behavioral changes in MPTP-treated monkey model of Parkinson's disease.

Authors:  Elodie Durand; Odile Petit; Léon Tremblay; Cédric Zimmer; Véronique Sgambato-Faure; Carine Chassain; Marlène Laurent; Bruno Pereira; Céline Silberberg; Franck Durif
Journal:  Front Behav Neurosci       Date:  2015-02-26       Impact factor: 3.558

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.